The Changing Treatment Paradigm After Progression in Advanced \textit{EGFR}-Mutated NSCLC

Join us for the satellite symposium in Vienna on 5 December, 2016
07:30 – 08:30

Room: Stolz 2
Messe Wien Exhibition & Congress Center
Messeplatz 1
A-1021 Vienna – Austria

Expert perspectives from:

Moderator
\textbf{James Chih-Hsin Yang, MD, PhD}
Graduate Institute of Oncology
National Taiwan University
National Taiwan University Hospital
Taipei, Taiwan

Faculty
\textbf{Anders Mellemgaard, MD, PhD}
Copenhagen University Hospital
Herlev, Denmark

Faculty
\textbf{Howard West, MD}
Swedish Cancer Institute
Global Resource for Advancing Cancer Education (GRACE)
Seattle, Washington, USA

This presentation was approved by the IASLC 17th World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 17th World Conference on Lung Cancer. This presentation is not sponsored or endorsed by IASLC.
The Changing Treatment Paradigm After Progression in Advanced *EGFR*-Mutated NSCLC

**AGENDA**

- Introduction: The Path Forward in Advanced *EGFR*-Mutated NSCLC
- Emerging Algorithm for Advanced *EGFR*-Mutated NSCLC After Progression
- Best Practices for Managing Advanced *EGFR*-Mutated NSCLC After Progression
- Panel Discussion: Overcoming Obstacles Managing Advanced *EGFR*-Mutated NSCLC After Progression
- Conclusions and Questions

This activity is supported by an educational funding donation provided by AstraZeneca. This CME activity is jointly provided by Oakstone Publishing, LLC and PeerVoice. Please contact webmaster@peercme.com for more information.

© 2012-2016, PeerCME